HERZLIYA, Israel, and CALGARY, AB — Innocan Pharma Corporation, a pioneer in the pharmaceutical and biotechnology industries, received a patent in India covering a prolonged-release pharmaceutical formulation utilizing liposomes to encapsulate cannabinoids.
The patent protects Innocan’s synthetic cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of synthetic CBD into the bloodstream. LPT-CBD received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-investigational-new-drug meeting to advance its development as a non-opioid alternative for chronic pain management.
The Indian patent, granted in a pharmaceutical market estimated at US $55 billion (Bain & Company) complements Innocan’s global patent applications, strengthening the proprietary value of its novel liposome-based cannabinoid technology.
Developed jointly in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of cannabinoids.
“We are thrilled to receive our first granted patent for our proprietary technology,” said Iris Bincovich, chief executive officer. “This milestone highlights our innovation and we look forward to a series of anticipated global patent approvals.”
Barenholz, head of Innocan’s advisory board stated, “The approval of this patent is a testament to the dedication and expertise of our development teams in driving innovation. Liposomal synthetic cannabidiol (LPT-CBD) is the first drug product in our pipeline that we are currently advancing under this intellectual property portfolio.”
Dr. Eyal Kalo, Innocan’s research and development director, added, “LPT-CBD demonstrates sustained pharmacokinetics and has shown efficacy in multiple animal models of chronic pain. We are extremely proud of this granted patent and remain dedicated to advancing LPT-CBD as a non-opioid alternative for chronic pain management.”
About Innocan Pharma
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted online sales through its BI Sky Global Ltd. subsidiary.
